Table 1.
Safety and efficacy of radiofrequency ablation (RFA) for locally advanced pancreatic cancer (LAPC).
| Reference | Design | # pts | Age, yrs | Size, mm | Morbidity | 30-day Mortality | Median FU | Median OS |
|---|---|---|---|---|---|---|---|---|
| Cantore [21] ** | Prospective | 107 | N.S. | N.S. | 28.0% (n = 30) |
1.9% (n = 2) | N.R. | 25.6 months |
| D’Onofrio [24] ** | Prospective | 18 | mean 62.4 | mean 48.1 (25–86) | 0% | 0% | N.R. | N.R. |
| Frigerio [25] ** | Retrospective | 57 | med 63 | N.R. | 14% (n = 8) |
0% | N.R. | 19 months |
| Girelli [23] ** | Prospective | 50 | med 64.5 | med 40 (IQR 30–50) |
24% (n = 12) |
2% (n = 1) | 8 months | N.R. |
| Girelli [22] ** | Prospective | 100 | mean 64 | med 36 (IQR 30–45) |
26% (n = 26) |
3% (n = 3) | 12 months | 20 months |
| Paiella [26] ** | Retrospective | 30 | N.R. | N.R. | N.R. | 0% | 15 months | 19 months * |
pts = patients; FU = follow-up; OS = overall survival; med = median; IQR = interquartile range; N.S. = not specified (per group); N.R. = not reported; * median disease specific survival. ** All procedures in all studies were performed at one single center: the University of Verona Hospital Trust; given the overlapping date ranges patient data are likely (partially) re-reported.